TREATMENT OF PRURITUS (ITCH)
CLINICAL TRIAL | the abstract
Principal Investigator: Dr. Jennifer Cather
An open-label long-term safety study of Serlopitant for the treatment of pruritus (itch).
Chronic pruritus impacts quality of life. Participants 18 years and older were randomized to placebo or Serlopitant; patients rated their itch improvement over time. The study completed on Jan 21, 2020, and results is scheduled to publish in late 2020.
SOTA Formula Consideration Based on Data:
CBD helps treat painful itch. 20% of people will experience chronic pain associated with inflammatory diseases, neuropathies, or medications such as chemotherapy at some point in their life and is a significant cause of suffering. Learn more about the benefits of SOTA Sleep Tincture and SOTA Rebound and Reclaim for relief from itching.
Study dates: 2018